Indian Journal of Clinical Biochemistry

, Volume 31, Issue 1, pp 43–49 | Cite as

Protective Role of Bilirubin Against Increase in hsCRP in Different Stages of Hypothyroidism

Original Article


In conjunction with thyroxine, bilirubin may play an important role for regulation of hsCRP level and a consequent pro-inflammatory condition in hypothyroidism. In present study we evaluated the dependence of hsCRP changes on total bilirubin (BT) and fT4 level in thirty overt (OH) and thirty subclinical hypothyroidism (SH). Serum BT, hsCRP, thyroxine and TSH were measured in both groups and compared with forty control subjects. Serum values of TSH, hsCRP showed raised (P < 0.001 for both) values with lower levels for fT4 and BT (P < 0.001 and 0.03 respectively) in hypothyroid patients compared to the controls. ANOVA showed significant increments in TSH and hsCRP values with decreases in fT4 among the control, SH and OH groups respectively (P < 0.001). BT values showed decrease in OH group only in comparison to controls (P = 0.04). Regression analysis revealed that hsCRP was negatively dependent on fT4 (β = −0.35, P = 0.002) and serum bilirubin (β = −0.40 and P < 0.001 respectively). Univariate general linear model analysis showed this dependence persisted even when carried out distinctly in SH and OH groups separately (P < 0.001). TSH did not show any significant predictive value on the hsCRP level in either of these two tests. From these analyses we suggest that serum hsCRP is closely integrated to a lowered synthesis of bilirubin and fT4 in hypothyroid patients. Furthermore, this causal relationship is not only limited to overt but also extends to the SH.


hsCRP Serum bilirubin Overt hypothyroidism Subclinical hypothyroidism 



The study did not involve any type of internal or external funding. All resources and infrastructure were from the government hospital supplies for routine patient care service.

Research Involving Human Participants

Present study was carried out in strict compliance with the Helsinki Declaration for human studies formulated in 1975 and modified in 2000. The study was started after getting written permission from the Institutional Ethical Committee.

Informed Consent

Informed consents were obtained from all individual participants included in the study.

Conflict of Interest

The authors Dr. Suparna Roy, Dr. Ushasi Banerjee and Dr. Anindya Dasgupta declare that they have no direct or indirect conflict of interest related to this study. No conflict of interest is related to this study regarding any administrative, financial or authorship matter.


  1. 1.
    Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52(4):561–71.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005;288(5):H2031–41.CrossRefPubMedGoogle Scholar
  3. 3.
    Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–12.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002;25(11):2016–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia. 2004;47(8):1403–10.CrossRefPubMedGoogle Scholar
  6. 6.
    Onat A, Can G, Hergenc G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metabolism. 2008;57(2):207–14.CrossRefPubMedGoogle Scholar
  7. 7.
    Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.CrossRefPubMedGoogle Scholar
  9. 9.
    Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291(5):585–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Marfella R, Ferraraccio F, Rizzo MR, Portoghese M, Barbieri M, Basilio C, et al. Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism. J Clin Endocrinol Metab. 2011;96(4):1015–20.CrossRefPubMedGoogle Scholar
  12. 12.
    Acay A, Ulu MS, Ahsen A, Eroglu S, Ozuguz U, Yuksel S, et al. Assessment of thyroid disorders and autoimmunity in patients with rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 2014;14(3):182–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Nagasaki T, Inaba M, Shirakawa K, Hiura Y, Tahara H, Kumeda Y, et al. Increased levels of C-reactive protein in hypothyroid patients and its correlation with arterial stiffness in the common carotid artery. Biomed Pharmacother. 2007;61(2–3):167–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Czarnywojtek A, Owecki M, Zgorzalewicz-Stachowiak M, Wolinski K, Szczepanek-Parulska E, Budny B, et al. The role of serum C-reactive protein measured by high-sensitive method in thyroid disease. Arch Immunol Ther Exp (Warsz). 2014;62(6):501–9.CrossRefGoogle Scholar
  15. 15.
    Aksoy DY, Cinar N, Harmanci A, Karakaya J, Yildiz BO, Usman A, et al. Serum resistin and high sensitive CRP levels in patients with subclinical hypothyroidism before and after L-thyroxine therapy. Med Sci Monit. 2013;19:210–5.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Bell RJ, Rivera-Woll L, Davison SL, Topliss DJ, Donath S, Davis SR. Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease—a community-based study. Clin Endocrinol (Oxf). 2007;66(4):548–56.PubMedGoogle Scholar
  17. 17.
    Cerbone M, Capalbo D, Wasniewska M, Mattace Raso G, Alfano S, Meli R, et al. Cardiovascular risk factors in children with long-standing untreated idiopathic subclinical hypothyroidism. J Clin Endocrinol Metab. 2014;99(8):2697–703.CrossRefPubMedGoogle Scholar
  18. 18.
    Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem. 2000;46(11):1723–7.PubMedGoogle Scholar
  19. 19.
    Jung CH, Lee MJ, Kang YM, Hwang JY, Jang JE, Leem J, et al. Higher serum bilirubin level as a protective factor for the development of diabetes in healthy Korean men: a 4 year retrospective longitudinal study. Metabolism. 2014;63(1):87–93.CrossRefPubMedGoogle Scholar
  20. 20.
    Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994;40(1):18–23.PubMedGoogle Scholar
  21. 21.
    Deetman PE, Bakker SJ, Kwakernaak AJ, Navis G, Dullaart RP. The relationship of the anti-oxidant bilirubin with free thyroxine is modified by insulin resistance in euthyroid subjects. PLoS One. 2014;9(3):e90886.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Karthick N, Dillara K, Poornima KN, Subhasini AS. Dyslipidaemic changes in women with subclinical hypothyroidism. J Clin Diagn Res. 2013;7(10):2122–5.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Gunduz M, Gunduz E, Kircelli F, Okur N, Ozkaya M. Role of surrogate markers of atherosclerosis in clinical and subclinical thyroidism. Int J Endocrinol. 2012; PMCID: 3296143. doi: 10.1155/2012/109797.
  24. 24.
    Yang SS, Tang L, Li RG, Ge GH, Qu XK, Ma JW, et al. The effects of subclinical hypothyroidism on serum lipid level and TLR4 expression of monocyte in peripheral blood of rats. Neuro Endocrinol Lett. 2014;35(1):80–6.PubMedGoogle Scholar
  25. 25.
    Efstathiadou Z, Bitsis S, Milionis HJ, Kukuvitis A, Bairaktari ET, Elisaf MS, et al. Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial? Eur J Endocrinol. 2001;145(6):705–10.CrossRefPubMedGoogle Scholar
  26. 26.
    Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab. 2003;88(8):3731–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Turemen EE, Cetinarslan B, Sahin T, Canturk Z, Tarkun I. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocr J. 2011;58(5):349–54.CrossRefPubMedGoogle Scholar
  28. 28.
    Kalkan GY, Gur M, Baykan AO, Koyunsever NY, Kaypakli O, Sen O, et al. Serum bilirubin level and aortic intima-media thickness in patients without clinical manifestation of atherosclerotic cardiovascular disease. Angiology. 2014;65(4):308–12.CrossRefPubMedGoogle Scholar
  29. 29.
    Yu K, Kim C, Sung E, Shin H, Lee H. Association of serum total bilirubin with serum high sensitivity C-reactive protein in middle-aged men. Korean J Fam Med. 2011;32(6):327–33.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Hunt SC, Wu LL, Hopkins PN, Williams RR. Evidence for a major gene elevating serum bilirubin concentration in Utah pedigrees. Arterioscler Thromb Vasc Biol. 1996;16(8):912–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol. 1996;51(6):859–62.CrossRefPubMedGoogle Scholar
  32. 32.
    Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, et al. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation. 2005;112(7):1030–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Ollinger R, Yamashita K, Bilban M, Erat A, Kogler P, Thomas M, et al. Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle. 2007;6(1):39–43.CrossRefPubMedGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2015

Authors and Affiliations

  • Suparna Roy
    • 1
  • Ushasi Banerjee
    • 1
  • Anindya Dasgupta
    • 1
  1. 1.Department of BiochemistryCalcutta National Medical CollegeKolkataIndia

Personalised recommendations